Allergan, Adamas Pharmaceuticals, Amneal Pharmaceuticals deal

Allergan and Adamas granted Amneal rights to market on Jan. 1, 2025, generic versions of Namzaric memantine/donepezil to treat moderate to severe dementia in Alzheimer’s disease patients stabilized o...